194 related articles for article (PubMed ID: 31166706)
1. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
Trials; 2013 Apr; 14():91. PubMed ID: 23547564
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients.
Thangaraj SS; Thiesson HC; Svenningsen P; Stubbe J; Palarasah Y; Bistrup C; Jensen BL; Mortensen LA
Am J Physiol Renal Physiol; 2022 Feb; 322(2):F138-F149. PubMed ID: 34894724
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial.
Morales-Buenrostro LE; Ortega-Trejo JA; Pérez-Villalva R; Marino LA; González-Bobadilla Y; Juárez H; Zamora-Mejía FM; González N; Espinoza R; Barrera-Chimal J; Bobadilla NA
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F519-F528. PubMed ID: 31241992
[TBL] [Abstract][Full Text] [Related]
5. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Garg R; Kneen L; Williams GH; Adler GK
Diabetes Obes Metab; 2014 Mar; 16(3):268-72. PubMed ID: 24125483
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study.
Ojeda-Cervantes M; Barrera-Chimal J; Alberú J; Pérez-Villalva R; Morales-Buenrostro LE; Bobadilla NA
Am J Nephrol; 2013; 37(5):481-90. PubMed ID: 23635604
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
Nowak KL; Gitomer B; Farmer-Bailey H; Wang W; Malaczewski M; Klawitter J; You Z; George D; Patel N; Jovanovich A; Chonchol M
Am J Kidney Dis; 2019 Aug; 74(2):213-223. PubMed ID: 30803706
[TBL] [Abstract][Full Text] [Related]
8. Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
Hwang MH; Yoo JK; Luttrell M; Kim HK; Meade TH; English M; Talcott S; Jaffe IZ; Christou DD
Exp Gerontol; 2016 Jan; 73():86-94. PubMed ID: 26639352
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Donderski R; Stróżecki P; Sulikowska B; Grajewska M; Miśkowiec I; Stefańska A; Siódmiak J; Odrowąż-Sypniewska G; Manitius J
Int Urol Nephrol; 2017 Oct; 49(10):1867-1873. PubMed ID: 28710615
[TBL] [Abstract][Full Text] [Related]
10. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.
Quaschning T; Ruschitzka F; Shaw S; Lüscher TF
Hypertension; 2001 Feb; 37(2 Pt 2):801-5. PubMed ID: 11230376
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
13. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).
Mortensen LA; Thiesson HC; Tougaard B; Egfjord M; Fischer ASL; Bistrup C
BMC Nephrol; 2018 May; 19(1):105. PubMed ID: 29724188
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model.
Wang CC; Lee AS; Liu SH; Chang KC; Shen MY; Chang CT
BMC Nephrol; 2019 Sep; 20(1):351. PubMed ID: 31492107
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists and endothelial function.
Maron BA; Leopold JA
Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
[TBL] [Abstract][Full Text] [Related]
16. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
[TBL] [Abstract][Full Text] [Related]
17. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.
Bavry AA; Handberg EM; Huo T; Lerman A; Quyyumi AA; Shufelt C; Sharaf B; Merz CN; Cooper-DeHoff RM; Sopko G; Pepine CJ
Am Heart J; 2014 Jun; 167(6):826-32. PubMed ID: 24890531
[TBL] [Abstract][Full Text] [Related]
19. Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
Rajagopalan S; Alaiti MA; Broadwater K; Goud A; Gaztanaga J; Connelly K; Fares A; Shirazian S; Kreatsoulas C; Farkouh M; Dobre M; Fink JC; Weir MR
Clin Cardiol; 2017 Sep; 40(9):633-640. PubMed ID: 28555959
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.
Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ
Trials; 2014 May; 15():158. PubMed ID: 24886272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
